Streptococcus Agalactiae

Systemic Streptococcal Group B Disease Spreads In Norway

Published in Medical Letter on the CDC and FDA, October 28th, 2001

Norway has in the past years experienced an increasing incidence of systemic disease caused by group B streptococci (GBS, Streptococcus agalactiae) as monitored by notifications of positive blood culture and spinal fluid specimens to Norway's Meldingssystem for smittsomme sykdommer (MSIS) at Statens institutt for folkehelse (National Institute of Public Health, NIPH).

This epidemiological development parallels that of systemic group A streptococcal (GAS, S. pyogenes) disease and systemic pneumococcal (S. pneumoniae) disease. Norway's notification system is a two channel statutory system that combines clinical and laboratory notifications in one...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2001-10-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry